Is Genelux Corp. overvalued or undervalued?

As of 14 November 2023, Genelux Corp. has moved from a grade of risky to does not qualify. The company is currently considered overvalued, given its negative financial metrics and lack of profitability. Key ratios include a Price to Book Value of 3.27, an EV to EBIT of -2.00, and an EV to EBITDA of -2.06, all indicating significant financial distress.
In comparison to its peers, Genelux Corp. has a P/E ratio of -3.8576, while Viridian Therapeutics, Inc. also does not qualify with a P/E of -4.1277. Notably, Travere Therapeutics, Inc. is rated risky with a P/E of -5.5910, while PetIQ, Inc. stands out as fairly valued with a P/E of 27.1022. Despite a strong one-year stock return of 34.47% compared to the S&P 500's 10.26%, the fundamental metrics suggest that Genelux Corp. is not a sound investment at its current valuation.